Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Swift Treatment of Stage I Melanoma Aided Survival

J Am Acad Dermatol; ePub 2017 Oct 17; Conic, et al

Expeditious treatment of stage I melanoma is associated with improved outcomes, according to a recent study. Patients with stage I to III cutaneous melanoma and with available time to definitive surgery and overall survival were identified by using the National Cancer Database (n=153,218). The t test and chi-square test were used to compare variables; Cox regression was used for multivariate analysis. Researchers found:

  • In a multivariate analysis, patients in all stages who were treated between 90 and 119 days after biopsy and >119 days had a higher risk for mortality compared with those treated within 30 days of biopsy.
  • In a subgroup analysis of stage I, higher mortality risk was found in patients treated within 30 to 59 days, 60 to 89 days, 90 to 119 days, and >119 days after biopsy.
  • Surgical timing did not affect survival in stages II and III.

Citation:

Conic RZ, Cabrera CI, Khorana AA, Gastman BR. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. [Published online ahead of print October 17, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.08.039.